Subgroup analysis of RFS and CIR of 143 AML patients stratified according to pretreatment karyotype or FLT3 status and levels of MRD after consolidation. (A-B) Those with a level of residual leukemic cells < 0.035% are referred to as intermediate karyotype-MRD⁻, favorable karyotype-MRD⁻, or FLT-wt MRD⁻, whereas those with levels ≥ 0.035% are categorized as intermediate karyotype-MRD⁺, favorable karyotype-MRD⁺, or FLT-wt MRD⁺. Survival outcomes of these subsets and of U-RK and FLT3-ITD category are shown (P < .001 for all comparisons). (C-D) FLT-wt patients achieving a MRD-negative status show a better outcome than those who remained MRD-positive after consolidation (P < .001).